ID

12768

Descrizione

Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01162551

collegamento

https://clinicaltrials.gov/show/NCT01162551

Keywords

versioni (1)
  1. 21/12/15 21/12/15 -
Caricato su

21 dicembre 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Cancer NCT01162551

Inglese

Eligibility Cancer NCT01162551

1 moduli  
  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01162551
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients </= 25 years of age, at time of enrollment, with second or greater relapse of all or nhl. for all must have histologic diagnosis with >10% blasts in the marrow and for lymphoblastic lymphoma or peripheral t-cell lymphoma must have radiologic or physical evidence of recurrence.
Descrizione

age; Acute lymphocytic leukemia; recurrence

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0023449
UMLS CUI [3]
C0034897
lansky > 50% or karnofsky > 50%
Descrizione

Lansky Play-Performance Status; Karnofsky Performance Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1522275
UMLS CUI [2]
C0206065
negative pregnancy test
Descrizione

Pregnancy test negative

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0427780
creatinine clearance or radioisotope gfr > 70ml/min/m2 or serum creatinine based on age /gender
Descrizione

creatinine clearance; age; gender

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0373595
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0079399
pulse ox >94%
Descrizione

pulse oximetry

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0034108
total bilirubin <1.5 x normal for age
Descrizione

total bilirubin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201913
alt < 5 x normal for age
Descrizione

Alanine Transaminase

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1557189
albumin > 2g/dl
Descrizione

albumin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201838
shortening fraction by echo > 28% or ejection fraction > 50% by gated radionuclide study
Descrizione

ejection fraction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0489482
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient has known allergies to sirolimus,fk-506 or mtor inhibitors
Descrizione

hypersensitivity sirolimus

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0072980
patient is taking other investigational anti-neoplastic drugs
Descrizione

investigational anti-neoplastic drugs other

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1875339
patient received no myelosuppressive chemo within 14 days
Descrizione

chemotherapy myelosuppressive

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3665472
UMLS CUI [1,2]
C1513793
< 14 days have elapsed since local palliative xrt (small port) < 28 days since prior craniospinal xrt or 50% radiation of pelvis <28 days if other substantial bm radiation
Descrizione

radiotherapy palliative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0034619
UMLS CUI [1,2]
C1285530
hematopoietic growth factors within 7 days of entry (except erythropoietin.)
Descrizione

hematopoietic growth factors

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079490
patient has taken any biologic agents within 14 days
Descrizione

drug biologic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205460
post bmt/sct - evidence of active gvhd, at least > 3 months must have elapsed
Descrizione

Graft-versus-host disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018133
patient has uncontrolled infection (if patients with fungal disease, stable for < 14 days and patients with bacteremia without negative blood culture
Descrizione

bacteremia; infection uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004610
UMLS CUI [2,1]
C3714514
UMLS CUI [2,2]
C0205318
existing non-hematologic toxicities > grade 2
Descrizione

toxicity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0600688
use of steroids or hydroxyurea is permitted upto 14 days prior to entry.
Descrizione

steroids; hydroxyurea

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0020402
Ritorna all'inizio della pagina

Similar models

Eligibility Cancer NCT01162551

1 moduli
  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01162551
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
age; Acute lymphocytic leukemia; recurrence
Item
patients </= 25 years of age, at time of enrollment, with second or greater relapse of all or nhl. for all must have histologic diagnosis with >10% blasts in the marrow and for lymphoblastic lymphoma or peripheral t-cell lymphoma must have radiologic or physical evidence of recurrence.
boolean
C0001779 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
C0034897 (UMLS CUI [3])
Lansky Play-Performance Status; Karnofsky Performance Status
Item
lansky > 50% or karnofsky > 50%
boolean
C1522275 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Pregnancy test negative
Item
negative pregnancy test
boolean
C0427780 (UMLS CUI [1])
creatinine clearance; age; gender
Item
creatinine clearance or radioisotope gfr > 70ml/min/m2 or serum creatinine based on age /gender
boolean
C0373595 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
pulse oximetry
Item
pulse ox >94%
boolean
C0034108 (UMLS CUI [1])
total bilirubin
Item
total bilirubin <1.5 x normal for age
boolean
C0201913 (UMLS CUI [1])
Alanine Transaminase
Item
alt < 5 x normal for age
boolean
C1557189 (UMLS CUI [1])
albumin
Item
albumin > 2g/dl
boolean
C0201838 (UMLS CUI [1])
ejection fraction
Item
shortening fraction by echo > 28% or ejection fraction > 50% by gated radionuclide study
boolean
C0489482 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
hypersensitivity sirolimus
Item
patient has known allergies to sirolimus,fk-506 or mtor inhibitors
boolean
C0020517 (UMLS CUI [1,1])
C0072980 (UMLS CUI [1,2])
investigational anti-neoplastic drugs other
Item
patient is taking other investigational anti-neoplastic drugs
boolean
C1875339 (UMLS CUI [1])
chemotherapy myelosuppressive
Item
patient received no myelosuppressive chemo within 14 days
boolean
C3665472 (UMLS CUI [1,1])
C1513793 (UMLS CUI [1,2])
radiotherapy palliative
Item
< 14 days have elapsed since local palliative xrt (small port) < 28 days since prior craniospinal xrt or 50% radiation of pelvis <28 days if other substantial bm radiation
boolean
C0034619 (UMLS CUI [1,1])
C1285530 (UMLS CUI [1,2])
hematopoietic growth factors
Item
hematopoietic growth factors within 7 days of entry (except erythropoietin.)
boolean
C0079490 (UMLS CUI [1])
drug biologic
Item
patient has taken any biologic agents within 14 days
boolean
C0013227 (UMLS CUI [1,1])
C0205460 (UMLS CUI [1,2])
Graft-versus-host disease
Item
post bmt/sct - evidence of active gvhd, at least > 3 months must have elapsed
boolean
C0018133 (UMLS CUI [1])
bacteremia; infection uncontrolled
Item
patient has uncontrolled infection (if patients with fungal disease, stable for < 14 days and patients with bacteremia without negative blood culture
boolean
C0004610 (UMLS CUI [1])
C3714514 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
toxicity
Item
existing non-hematologic toxicities > grade 2
boolean
C0600688 (UMLS CUI [1])
steroids; hydroxyurea
Item
use of steroids or hydroxyurea is permitted upto 14 days prior to entry.
boolean
C0038317 (UMLS CUI [1])
C0020402 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial